EE644 Budget Impact of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the US

Nirmatrelvir/ritonavir (NMV/r) is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19. NMV/r has also been authorized for emergency use by FDA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19.

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Sandin, D. Veenstra, M. Dzingina, M. Vankelegom, S. Sullivan, D. Campbell, C. Ma, C. Harrison, F. Draica, T.L. Wiemken, T. Mugwagwa Source Type: research